Cullin 2 antibody (AA 18-182)

Catalog No. ABIN968173

Product Details anti-Cullin 2 Antibody

Target: Cullin 2 (CUL2)

Binding Specificity: AA 18-182

Reactivity: Human, Mouse, Rat, Dog

Host: Mouse

Clonality: Monoclonal

Conjugate: This Cullin 2 antibody is un-conjugated

Application: Western Blotting (WB), Immunohistochemistry (IHC), Immunofluorescence (IF), Immunoprecipitation (IP)

Cross-Reactivity: Mouse (Murine), Rat (Rattus), Dog (Canine)

Characteristics: 1. Since applications vary, each investigator should titrate the reagent to obtain optimal results.
2. Please refer to us for technical protocols.
3. Caution: Sodium azide yields highly toxic hydrazoic acid under acidic conditions. Dilute azide compounds in running water before discarding to avoid accumulation of potentially explosive deposits in plumbing.
4. Source of all serum proteins is from USDA inspected abattoirs located in the United States.

Purification: The monoclonal antibody was purified from tissue culture supernatant or ascites by affinity chromatography.

Immunogen: Human CUL-2 aa. 18-182

Clone: 4-CUL

Isotype: IgG1

Application Details

Comment:

Related Products: ABIN968537, ABIN967389

Restrictions: For Research Use only

Handling

Format: Liquid

Concentration: 250 μg/mL

Buffer: Aqueous buffered solution containing BSA, glycerol, and ≤0.09 % sodium azide.

Preservative: Sodium azide

Precaution of Use: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Storage: -20 °C

Storage Comment: Store undiluted at -20° C.

References for anti-Cullin 2 antibody (ABIN968173)

Saitoh, Pizzi, Wang: "Perturbation of SUMOlation enzyme Ubc9 by distinct domain within nucleoporin RanBP2/Nup358." in: The Journal of biological chemistry, Vol. 277, Issue 7, pp. 4755-63, (2002) (PubMed).

Pause, Lee, Worrell, Chen, Burgess, Linehan, Klausner: "The von Hippel-Lindau tumor-suppressor gene product forms a stable complex with human CUL-2, a member of the Cdc53 family of proteins." in: Proceedings of the National Academy of Sciences of the United States of America, Vol. 94, Issue 6, pp. 2156-61, (1997) (PubMed).

Target Details for Cullin 2

Target: Cullin 2 (CUL2)

Alternative Name: CUL-2 (CUL2 Products)

Synonyms: cul2 antibody, Cullin-2 antibody, fj48a06 antibody, wu:fj48a06 antibody, cullin-2 antibody, LOC100221330 antibody, 1300003D18Rik antibody, 4932411N15Rik antibody, AI327301 antibody, mKIAA4106 antibody, ATCUL2 antibody, F22D16.2 antibody, F22D16_2 antibody, cullin 2 antibody, cullin 2 antibody, cullin-2 antibody, putative cullin-2 (cul-2) antibody, cullin 2 L homeolog antibody, Cullin-2 antibody, cul2 antibody, CUL2 antibody, PTRG_05231 antibody, Smp_079740 antibody, LOC100550749 antibody, Cul2 antibody, cul2.L antibody, cul-2 antibody

Background: The cullins are a family of proteins that are integral to cell cycle regulation. Members of this family include human Cul-2, C.elegans Ce-Cul-1, and S. cerevisiae Cdc53. Proper control of cell cycle progression is essential for the prevention of tumorigenesis. Mutant forms of both Ce-Cul-1 and Cdc53 have been implicated in the oncogenic process. Abnormal nuclear localization of Cul-2 is seen in a rare hereditary condition known as VHL (von Hippel-Lindau) syndrome. Patients with VHL syndrome possess a mutant VHL gene and develop cancers such as retinal anginomas, CNS hemangioblastomas, and renal cell carcinomas. In normal cells, the VHL protein competes with subunit A of elongin, a transcription elongation factor, for binding to subunits B and C. The formation of the VHL-B-C complex inhibits elongation. Additional data indicates that this complex associates with CUL-2 and promotes CUL-2 nuclear translocation. In cells with mutated VHL, transcriptional elongation is not efficiently curtailed and CUL-2 is not properly localized in the nucleus. Therefore, CUL-2 mediates VHL function, suggesting CUL-2 may be a candidate human tumor suppressor. This antibody is routinely tested by western blot analysis.
Synonyms: Cullin-2

Molecular Weight: 76 kDa

Pathways: M Phase, Asymmetric Protein Localization, SARS-CoV-2 Protein Interactome